Lung Cancer Mutation Panel
Doctor explaining chart to senior woman patient

EGFR, KRAS and EML4-ALK. Predict eligibility for non-small cell lung cancer (NSCLC) targeted therapies with this. Help assess patients with NSCLC being considered for treatment with an EGFR TKI.

Molecular & Genetic Testing
physician listening to patient's heart

As the world’s leader in cancer diagnostics, we have extensive capabilities in molecular and genetic testing, including FISH (fluorescence in situ hybridization) testing for early detection of lung cancer.

Lung cancer test summary

Test highlight- ROS1

Lung cancer is the leading cause of cancer-related deaths in the United States, and Non-small cell lung cancer (NSCLC) accounts for over 85% of all cases. Some NSCLC patients may benefit from targeted drug therapy based on specific genetic alterations in their tumors. Detection of ROS1 rearrangements in patients with NSCLC suggests eligibility for treatment with the tyrosine kinase inhibitor crizotinib.

For more details of ROS1 test, please see the test summary.

Aurelia Meloni-Ehrig, PhD, DSc

WEBINAR: Lung Cancer Why Fish for ALK Testing (and PCR for EGFR and KRAS) in NSCLC?

Dr. Aurelia Meloni-Ehrig, Chief Director, Cytogenetics, AmeriPath discusses the NSCLC-specific mutation panel and its potential benefits and compares and contrasts EML4-ALK mutation testing methodologies and communicates the advantages offered by FISH.

lungs illustration

Online Presentation

Dr. Dr. Govindan, Professor of Oncology, Washington University, shares Insights on Targeting Lung Cancer. How to harness to the potential of targeted therapy for lung cancer, the leading cause of cancer-related deaths.

healthcare professional using laptop

Test Interpretation Guides

See our guides for details on test selection, utilization, and interpretation. All information is based on peer-reviewed publications and practice guidelines.